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Abstract
The purpose of this project was to improve statin therapy adherence among diabetic patients
aged 65 and older treated at a small family practice clinic in western San Antonio. Additionally,
the project aimed to decrease low density lipoprotein cholesterol levels in this patient population
as recommended to 70 mg/dl or less. Diabetic patients are more likely to die from a cardiac event
than patients without diabetes. Statin therapy is an important factor in lowering cholesterol,
which reduces the patient’s risk for atherosclerosis. Educating patients aged 65 and older about
the role of statin therapy in preventing cardiovascular events, stroke, and vascular compromise
may increase medication adherence in this population, resulting in appropriate low density
lipoprotein levels for prevention of these serious comorbidities. 135 chart reviews took place,
from which thirty-three patients were identified for the education intervention. The patients were
screened for medication adherence using the Morisky Medication Adherence Scale survey before
and after the intervention period to measure adherence to statin therapy. Education about
cholesterol and statin therapy was provided during the patient appointment, and a handout was
provided for reinforcement of education. Low density lipoprotein levels were drawn by the clinic
laboratory before and after the intervention period to measure improvement. Results showed
significant medication adherence increase and low density lipoprotein level decrease among
project participants after the 10-week implementation, though the target low density lipoprotein
level of 70 mg/dl or less was not met.
Keywords: hyperlipidemia, diabetes, T2DM, statin therapy, cardiovascular disease, medication
adherence
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Diabetes and cardiovascular disease are two of the most common causes of death
worldwide, and though there have been many medical advances in treatment of these two
diseases, patients 65 years and older with diabetes remain at high risk for death due to
cardiovascular disease. The internet has expanded the amount of knowledge and
recommendations open to the world; however, this vulnerable population is not one that is
familiar with the worldwide web. In many instances, paper education is still a valuable tool that
can be utilized to educate patients in this age range.
Many patients 65 years and older are victims of polypharmacy, and this can lead to
decreased medication adherence. As a result, these patients are at higher risk of cardiovascular
disease not only because they do not know how to use the internet to find educational
information, but because they may forget to take their cholesterol medication or they cannot
afford it because of all of the other medications they may be taking concurrently.
Statement of the Problem
Type 2 diabetes mellitus (T2DM) is a chronic disease associated with issues such as a
sedentary lifestyle and nutritional mismanagement of dietary patterns (Osonoi et al., 2016).
T2DM affects anywhere from 341 million to 371 million people in the world (Mohammed, AlHaj, Phung, Sun & Morisky, 2016), and heart disease is the leading cause of death worldwide
(Osonoi et al., 2016). Most patients diagnosed with T2DM are not knowledgeable about the
disease and fail to implement a healthy lifestyle. This pertains to adherence to medications that
can control the disease and prevent further complications as well. Complications of T2DM
include heart disease, stroke, renal failure, peripheral neuropathy and extremity amputation, and
diabetic retinopathy which can ultimately cause blindness (Jalilian, Motlagh, Solhi, &
Gharibnavaz, 2014). Proper management of T2DM can lead to better quality of life, and

8

STATIN THERAPY QUALITY IMPROVEMENT INITIATIVE

9

prevention of comorbidities that can increase incidence of morbidity and mortality related to the
complications of this disease.
One of the most frequently encountered comorbidities of T2DM, and one of the most
fatal, is cardiovascular disease. Cardiovascular disease pertains to disease of the veins, arteries,
and the heart, and is mostly due to atherosclerosis. Atherosclerosis is defined by the American
Heart Association as a condition that develops when plaque made of cholesterol builds up in the
walls of the arteries and makes them narrow and inflexible (American Heart Association, 2016).
This makes it extremely difficult for blood to flow, and with less area to pass through, it is easier
for a blood clot to form, causing a heart attack, and in the brain, a stroke (American Heart
Association, 2016).
Both the American Heart Association and the American Diabetes Association
recommend the initiation of statin therapy in the diabetic patient, as these patients are at high risk
for cardiovascular disease related to atherosclerosis. However, when patients are given one more
medication that is not for something already affecting their overall health, this generally does not
persuade them to take said medication. The medications these patients have already been issued
to control their T2DM not taken either because they feel fine or they have forgotten. Medication
adherence is a major concern, as it is estimated that close to 50% of diabetics are non-compliant
with medications of some sort (Mohammed et al., 2016). Non-adherence to medications can lead
to hospitalization, emergency interventions, and even death (Mohammed et al., 2016). Some
predictors of medication non-adherence are difficulty reading prescription labels, increased
intensity of treatment, increased symptom burden, inadequate self-monitoring, and inadequate
disease knowledge (DiBonaventura, Wintfield, Huang, & Goren., 2014). The risk for CVD can
be decreased by living a healthy lifestyle with proper diet and exercise, and adherence to
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medications, including the statins prescribed in order to lower LDL cholesterol and raise HDL
cholesterol levels.
Background and Significance
In the United States, cardiovascular disease (CVD) leads to more than 2,000 deaths per
day and costs 108.9 billion dollars per year due to health care services, medication costs, and lost
productivity of the affected individuals (Moore, Fuller, & Thanavaro, 2015). Dyslipidemia is a
leading risk factor for CVD, and more than 32 million Americans 20 years and older have
elevated blood cholesterol levels (Moore et al., 2015).
In 2012, more than 29 million Americans had diabetes (9.3% of the U. S. population),
and more than 8 million were unaware of the diagnosis (American Diabetes Association, 2016).
The death rate due to cardiovascular disease is 1.7 times greater for diabetics than people without
a diagnosis of diabetes (American Diabetes Association, 2016). People living with diabetes with
high cholesterol levels are at a much greater risk of dying from a cardiovascular complication
than people without diabetes.
In Texas, there are approximately 1.8 million people who are currently diagnosed with
diabetes, which is 13% of the state’s population (University Health System, 2017). More than
400,000 people living with diabetes in Texas are undiagnosed (University Health System, 2017).
In Bexar County alone, 11.8% of the population is diagnosed with diabetes, which is more than
130,000 individuals (University Health System, 2017). Control of diabetes in this patient
population is especially important, as diabetes is the fourth leading cause of death in Bexar
County. Heart disease is the leading cause of death in the United States, in Texas, and in Bexar
County as well (San Antonio Metropolitan Health District, 2009).
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Control of LDL cholesterol is improving in the diabetic population receiving treatment.
Forty-five percent of United States residents treated for hypercholesterolemia were controlled
with an LDL level <100 mg/dl between 1999 and 2000, which raised to 63.6% in 2009 and 2010
(Farsaei et al., 2015). However, the improvement of HDL levels does not follow this increase,
and remains problematic for those at risk, especially those with T2DM. Statin therapy not only
decreases LDL cholesterol, but raises HDL cholesterol as well (American Heart Association,
2016). Diet and exercise are the most effective lifestyle changes that can be made to lower LDL,
increase HDL, and decrease risk for CVD (Macias Saint-Gerons et al., 2014). Not every patient
will adhere to an appropriate diet and exercise regimen, however, and initiation of statin therapy
for patients with increased risk as an adjunct to diet and exercise is appropriate for prevention of
CVD in the diabetic patient.
One of the major predictors listed above that may cause a person diagnosed with diabetes
to adhere to a medication regimen is lack of disease knowledge. Some studies have shown that
education sessions provided to patients with diabetes can improve overall health knowledge and
increase medication compliance rates. One study, in particular, conducted in the United Arab
Emirates, utilized a 30-minute education session led by a diabetic educator that focused on the
importance of adherence in addition to defining the disease process, talking about the
medications prescribed and what they do inside the body, and answering any questions the
participants had about the specific medications they were taking (Mohammed et al., 2016). The
results of the study were significant for improvement of medication compliance in the
intervention group (Mohammed et al., 2016). Another study conducted in Iran for diabetic
patients used the Health Belief Model to educate patients about their disease in order to improve
compliance to medications, and this intervention included six separate education sessions
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pertaining to disease knowledge (Jalilian et al., 2014). Results showed that if patients were truly
worried about their disease process and the complications, more effort would be taken to
improve health outcomes by the patients. The American Diabetes Association estimates the
complications and costs of diabetes could be decreased significantly simply by increasing patient
awareness and educating to improve prevention of comorbidities (Jalilian et al., 2014). If diabetic
patients are non-adherent to diabetic medications, they are likely non-compliant with
medications to prevent a disease they do not already have.
Several studies have been conducted in the United States as well, including a large prepost cohort study conducted at the Cleveland Clinic in which significant regression of coronary
atheroma and reduction of cardiovascular events was shown using ultrasound analysis in patients
prescribed moderate to high intensity statin therapy (Stegman, Puri, Shao, & Nicholls, 2014).
Improvement was shown in all patients, including patients with T2DM. The national guidelines
for practice produced by the American Heart Association and the American College of
Cardiology strongly recommend initiating statin therapy in patients with T2DM aged 40 years
and older, as the evidence shows that statin therapy is effective in decreasing bad cholesterol
levels while raising good cholesterol levels in order to prevent cardiovascular disease (Stone et
al., 2014).
Assessment
The family practice clinic in which the quality improvement project was implemented is
run by a group of 3 physicians, and 11 support staff including 1 practice administrator, 1 office
manager, 3 administrative staff members, and 6 medical assistants. One diabetic educator is
available 3 days per month for patient classes. Medicare and Medicaid are accepted, as well as
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all other commercial insurances. The clinic has several contracts with managed care plans for
patients aged 65 years and older for comprehensive disease management and primary care.
Stakeholders are people or groups of people that have a vested interest in clinical
decisions and improvements related to evidence supporting clinical decisions (Agency for
Healthcare Research and Quality, 2014). The main stakeholders of this family practice clinic are
the patients and families of patients, providers and support staff, and payers such as employers
and insurance companies. The patients’ interests in the clinic stem from a concern for which
aspects of the illness are most severe, what treatments are the most effective, and which options
are the easiest to implement and maintain (Agency for Healthcare Research and Quality, 2014).
Providers are the decision-makers, and they aim existing holes in the data pertaining to best
treatment options and most harmful interventions, for the safe and effective management of
patients (Agency for Healthcare Research and Quality, 2014). Providers must maintain an
appropriate knowledge base to make the best treatment recommendations and must stay current
on the most recent evidence-driven guidelines to provide quality care (Agency for Healthcare
Research and Quality, 2014). Payers want to ensure that patients are treated with the best
evidence-based treatment for expedition of healing, return to normal function, and to prevent
complications related to disease processes that could increase direct and indirect costs of medical
care (Agency for Healthcare Research and Quality, 2014). All stakeholders involved have a
vested interest in the success of medical treatment and should support evidence-based practice
and quality improvement measures.
Patients of all ages are seen in the clinic, from pediatrics to geriatrics, with the majority
age ranging from 42 to 77 years. There are 848 patients aged 65 years and older seen in this
primary care clinic. The current percentage of patients with diabetes mellitus with LDL-C levels
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of 70 mg/dl or less is 35.6%. The aim is to increase the percentage of patients with diabetes
mellitus with LDL-C levels of 70 mg/dl or less to 70%.
The “2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce
atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guideline” states that patients with diabetes
mellitus should have lipid panels drawn every 3 to 12 months, and 10 to 12 weeks after the
initiation of statin therapy (Stone et al., 2014). Moderate intensity statin therapy should be
initiated for patients aged 40 to 75 years with LDL-C levels of 70 mg/dl to 189 mg/dl (Stone et
al., 2014). High intensity statin therapy should be initiated for patients aged 40 to 75 years with
LDL-C levels of 190 mg/dl or greater (Stone et al., 2014). In order to appropriately manage
diabetic patients at risk for cardiovascular disease, evidence indicates that statin therapy should
be prescribed when indicated.
Organizational Readiness for Change
The Practice Improvement Capacity Rating Scale is a tool for assessing readiness of an
organization for implementation of quality improvement measures that scores a practice overall
in colors, with the color red correlating to not ready, yellow to limited capacity for change, and
green correlating to ready and capable for implementation of quality improvement measures
(Robert Wood Johnson Foundation, 2014). In using this tool, one must first determine who to
interview at the practice. The scoring of the tool not only has an overall color of red, yellow, or
green, but each criterion is weighted on a scale of 1 to 3, with 1 being lowest importance and 3
being the highest importance (Robert Wood Johnson Foundation, 2014). All criteria with a
weight of 3 must be passed by the organization in order to receive a score of green. The clinic
received an overall score of 255 by multiplying the scored questions by the weight of the
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questions and adding each category to this total score. A score of 255 is considered green
according to the scale, which indicates that the clinic ready and capable for QI work immediately
(Robert Wood Johnson Foundation, 2014).
Project Focus
The primary objective of this project is to improve the percentage of diabetic patients
aged 65 years and older with a LDL-C level of 70 mg/dl or less from 35.6% to 70% and a statin
therapy adherence rate increase from 20% to 90% by August 10, 2017. The secondary objective
is to increase the percentage of diabetic patients aged 65 and older prescribed statin therapy from
62.6% to 80% by August 10, 2017. In order to accomplish these goals, the LDL-C level was
drawn and measured in the blood prior to the quality improvement measure implementation in
June 2017 and after the completion of the measure implementation on August 10, 2017. The
participants will complete the MMAS-8 survey to assess patient medication adherence prior to
the start of the improvement measure in June 2017 and again after the project completion on
August 10, 2017.
Summary and Strength of the Evidence
The evidence for this project consists of 8 articles from peer-reviewed journals. Included
in these eight articles is one clinical practice guideline, four cohort studies, one correlational
study, and two descriptive studies. The findings are consistent for support of education for
improving medication adherence in the diabetic patient population. There is also evidence for
effectiveness of statin therapy in preventing cardiovascular disease. The overall strength of the
articles is acceptable to use as evidence to support this project.
Several studies done in other countries, such as Iran, Spain, Japan, and the United Arab
Emirates, support initiation of healthy lifestyle choice including diet and exercise (Osonoi et al.,
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2016), and initiation of statin therapy for management of dyslipidemia in patients at risk for
CVD (Macias Saint-Gerons et al., 2014). Adherence is not a problem common to patients in the
United States with T2DM, but common to many countries. Level 4 evidence in the form of a
large cohort study in the United Arab Emirates indicated that adherence could be improved using
educational sessions about T2DM, its associated risk factors, and recommended treatment
regimens (Mohammed et al., 2016).
A large clinical trial conducted at the Cleveland Clinic in the United States compared
rosuvastatin and atorvastatin on regression of coronary atheroma in diabetic and non-diabetic
patients. It showed a significant improvement in patients with established atherosclerosis taking
one of these medications over the course of 24 months, with intravascular ultrasound
measurements taken to visualize regression of plaque in the arteries (Stegman et al., 2014). The
evidence in this study, a controlled trial over 2 years, is graded Level 3 for strength of evidence.
This study does include the diabetic patient, and is reliable for generalization of statin therapy for
the T2DM population.
National guidelines are in place for initiation of statin therapy for cholesterol
management of diabetic patients with LDL levels >70 mg/dl. This strength of evidence is Level
1, and the recommendations include statin therapy for T2DM patients with elevated LDL levels
to include moderate to intensive statin therapy (Stone et al., 2014).
The evidence is international in support of utilization of statin therapy in the diabetic
population in order to control overt CVD and to prevent CVD in those not yet affected by this
complication. It is important to control the risk for all complications in T2DM patients, and with
heart disease holding fast to its rank as the leading cause of death in the general population, this
complication becomes one of ultimate importance for people living with T2DM.
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Methods
Project Intervention
In order to accurately measure the improvement of LDL-C cholesterol levels in the
diabetic population aged 65 and older in this clinic, a review of electronic medical records took
place to retrieve the baseline cholesterol levels from previous laboratory studies taken. During
the patient’s regularly scheduled appointment, the MMAS-8 was completed by the patient as part
of normal patient care routine for the purpose of measuring medication compliance. During the
patient appointment, an education handout pertaining to cholesterol control and cardiovascular
disease prevention was given to the patient scoring a 6 or less on the MMAS-8 when discussing
current statin therapy increase or initiation of statin therapy for prevention of cardiovascular
disease.
Patients were scheduled for return appointment at the end of the intervention
implementation period for a redraw of blood in laboratory for LDL-C levels and reissued the
MMAS-8 to assess for improvement in medication compliance. The scores were assessed and
evaluated for significant improvement in LDL-C levels and medication adherence in order to
ensure optimal outcomes for this population.
In order to confirm that the project, if successful, can be sustained by the providers and
other staff members, a 30-minute staff meeting was held in which the project was explained,
including each person’s role. The providers will participate in the initial education session during
the patient appointments to ensure continuity of care. All staff members were educated on how to
find the handouts for education at the American Diabetes Association website.
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Organizational Barriers and Facilitators
This clinic possesses many strengths that can facilitate successful completion of this
quality improvement measure. The staff utilizes the electronic health record consistently, which
makes it easier to track the overall health of the patient population, and to track which areas may
need further attention. Parts of the electronic health record are available to patients through the
patient portal as well, making it easier for them to read and interpret their own test results and to
assist in their own care plan. The clinic has a strong reputation in the community, and there is
facilitation of trust between patients, families, and providers. Trust is apparent between members
of the health care team in the clinic, which should make it simpler to provide quality overall
patient care. Network partnerships exist with managed care plans for the aging population seen
in the organization, which makes more resources available to provide a holistic model of care.
The office is run efficiently, with short wait times for patients and decreased stress on providers
and support staff. All three providers are proficient in the Spanish language. This facilitates trust
between patients seen in the clinic who speak English as a second language or not at all. Fluency
in Spanish also allows the providers to appropriately educate the entire patient population seen in
this organization. The clinic has a number of patients with multiple chronic conditions, such as
diabetes, and with the assistance of the diabetic educator the clinic is able to provide quality care
from an interdisciplinary approach.
Some weaknesses were also discovered in this organization. There is a lack of written
educational materials available in the clinic waiting area or examination rooms. Written
education is a supplement for providers that can assist the health care team in ensuring the
patient retains education initiated during patient appointments. The continuity of care for some
patients who do not come to scheduled appointments is an area of concern, as some patients with
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chronic conditions are not attending recommended follow-up appointments to evaluate progress
of disease management and medication adherence. Medication cost is an issue identified by some
of the staff members in the organization, as they have spoken with patients who are concerned
that they will not be able to afford all of the medications required to control their conditions and
achieve optimal outcomes. Some procedures a patient may require, such as radiological
examinations, have to be done off premises as these resources are not available in this clinic
setting, which can be a barrier to appropriate disease management of some patients. The clinic is
growing in patient number, however the small space allotted in the building for the clinic makes
it difficult to expand the number of patients accepted into the practice. There is limited funding
available to expand the clinic to a larger space, which poses another obstacle to providing care to
a larger patient population. Lastly, slowed access to referred specialist consultations for patients
with chronic disease management can impede the holistic approach to care for these individuals.
The west side of San Antonio is a growing community, with new homes being
constructed daily and new businesses opening everywhere. Given this growing community, the
patient population is expected to grow. With this clinic’s positive reputation, many new patients
are expected to choose this clinic as a primary care home for health care needs. A large part of
the growing population is in the age range of 65 years and older, and these patients are choosing
managed care plans that may have established partnerships with the organization. Urgent care
centers, free-standing emergency rooms, and a small community hospital already exist in the
area, as well, which could lead to more referrals post-discharge for follow-up care or
establishment of primary care.
Some external threats have been established through the SWOT analysis for this family
practice care setting. The number of specialty physicians on this side of the city are fewer than
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the number needed, and the wait for patient referrals may be extended, leaving the primary care
provider with the responsibility of managing multiple chronic conditions in some patients
awaiting specialty care. Also, the patients are allowed to choose a primary care provider, and
there are many choices for such care on the west side of San Antonio. Patients without insurance
due to unemployment or other factors may not be able to seek primary care because of the
inability to afford health care costs associated with clinic visits. Insurance companies also
reimburse these organizations according to value-based care plans in some instances, and this
may lead to decreased income for fee-for-service clinics.
This primary care clinic has the potential to make a difference and to utilize evidencebased measures to improve the quality of health care in the area, and there are many barriers and
facilitators to the achievement of this goal, as listed above. Knowledge of the clinic’s internal
strengths and weaknesses, as well as external opportunities and threats will aid in completion of
a successful quality improvement intervention.
Results
A total of 14 males (42.4%) and 19 females (57.6%), aged 65 years and older participated
in the project. 16 participants were White (48.5%), 11 Hispanic (33.3%), 4 African American
(12.1%), and 2 Asian/Pacific Islander (6.1%). All 33 participants had both an active diagnosis of
diabetes mellitus and hyperlipidemia.
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Table 1
Demographic Characteristics of Study Participants
Characteristic
Gender
Male
Female

Percentage

Ethnicity
Caucasian
Hispanic
African American
Asian/Pacific Islander

Mean
1.58

SD
0.50

1.97

1.05

42.40
57.80

48.50
33.30
12.10
6.10

Note. SD = Standard Deviation
Control of Cholesterol
After the 10-week project implementation period, LDL-C levels of less than 100 mg/dl
were controlled 42.4% of the time, a 21.2% increase of the pre-intervention control rate of
21.2%. The LDL-C control for diabetic patients aged 40 and up is recommended to remain at 70
mg/dl or less, and this was found in only 12.1% of the participants. However, this small
percentage is an increase of 12.1% since none of the participants were controlled at less than 70
mg/dl. Table 2 represents LDL-C levels before and after implementation.
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Table 2
LDL-C Laboratory Values Before and After Education Intervention
Patient Number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

Pre-Intervention
LDL-C
127
95
87
135
121
140
111
119
106
183
81
158
137
130
99
109
77
108
281
132
98
153
206
120
97
163
103
135
140
132
188
118
140

Post-Intervention
LDL-C
98
64
64
102
94
148
114
96
108
166
64
122
116
88
98
74
78
92
177
133
64
115
127
119
84
104
112
128
101
120
118
78
102

Mean
SD

131.18
25.56

105.09

Note. SD = Standard Deviation
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Adherence to Statin Therapy Regimen
Medication adherence improved among the group of participants from 0% to 34.46%.
This percentage increase was calculated using the formula (y2-y1)/y1x100. For statistical
analysis of the MMAS-8 scores, a paired t-test was utilized to determine significance of the
difference in scores pre- and post-implementation of the project among participants. The results
were consistent with the desired outcome, in that post-intervention adherence scores (M = 5.36,
SD = 0.82) were higher than the pre-intervention adherence scores (M = 7.21, SD = 0.22). The
difference between pre- and post-implementation scores was statistically significant (M = -1.85,
SD = 1.35, t (32) = -7.87, p < .05). Table 3 displays the paired t-test statistical analysis for
medication adherence scores before and after the intervention.
Table 3
Medication Adherence Paired T-Test Results

Mean SD
-1.85 1.35

SEM
0.24

95% CI for Mean
Difference
Lower
Upper
-2.33
-1.37

t
-7.87

df
32

Participants’ MMAS-8
score pre- and postintervention
Note. SD = Standard Deviation, CI = confidence interval, SEM = Standard Error of the Mean.
*p < .05.
Although the target LDL-C level recommended by the American College of Cardiology
and the American Heart Association of 70 mg/dl or less was not met, this project’s duration was
limited at only 10 weeks. Given more time, if adherence is maintained, this population could
very well meet the target LDL-C level.
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Discussion
The MMAS-8 medication adherence scale was consistently given to patients that entered
the office over the age of 65 with a diagnosis of diabetes and hyperlipidemia over the first 2
weeks of project implementation. This was necessary because the implementation of education
handout and information session during scheduled appointments could not proceed without an
adherence scale in which to score the patient’s baseline. The intake period of 2 weeks was
necessary in order to have enough time to follow up in the same 10-week period and re-score the
patients using the MMAS-8 scale.
Of these 35 patients selected, 35 received education handouts and materials based on the
MMAS-8 score of 7 or less. At the end of the 10-week implementation period, these patients
were rescreened with MMAS-8 during the follow-up appointment. The percentage increase of
34.46% indicates that many of these patients did make adjustments to his or her daily routine
based on the education handout and session provided. The LDL-C levels, for the most part,
showed this change in lifestyle with the correlation of decreased laboratory values, though the
goal value of 70 mg/dl was not met.
Improvement of patient knowledge is a basic plan for controlling diabetes and
complications from the disease (Jalilian et al., 2014). Verbal discussion about risks for
cardiovascular disease and what that means for the patient, as well as a printed handout from the
American Diabetes Association about cholesterol did show reduction in laboratory values and
improved adherence over the 10-week implementation period.
Statin therapy has been proven to reduce the risk of cardiovascular events (Stegman et al.,
2014). If the medication is only taken every other day, the patient does not receive the full
benefit of the drug. Poor adherence at the beginning of this study, with scores of 7 or less on the
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MMAS-8, did correlate with LDL-C levels above the recommended target LDL-C of 70 mg/dl.
With improved adherence, the LDL-C levels did decrease as hoped, and did meet the in 4
participants of the original 35 patients selected (11.43%).
Limitations
The sample size of this project was small with only 35 participants, due to the time limit
of 10 weeks for implementation. No earlier implementation could have taken place, as there was
time allotted to educate and train staff members about the project and what each person’s role
would be. Patients who were initially screened and did not follow up were not included in the
final number of participants, because there was no way to measure adherence for these
individuals. The short time allotted for implementation of the project is also considered a
limitation. A longer time period for implementation may result differently.
Recommendations
Out of 52 patients screened with MMAS-8, 35 scored at or 7 or below in a 2-week time
period, and hence received an education session and a paper handout about cholesterol and
cardiovascular disease prevention. Diabetic patients need education about the risk for cardiac
events related to diabetes, and if only 2 weeks yielded 35 patients from an age group of 65 and
older who were not adhering to his or her medication regimen, a longer study may produce more
patients with the same issue. This education should hence be provided as standard of care for the
patients seen in clinic with a diagnosis of diabetes and/or hyperlipidemia.
Implications for Practice
None of the 52 patients diagnosed with diabetes and hyperlipidemia were screened for
medication adherence prior to implementation of this quality improvement project. Of the
patients screened during the project implementation, 100% of patients were initially scored as
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non-adherent with a score of 7 or less on the MMAS-8. After implementation, the 0% adherence
rate increased to 45.71% after project completion, with 16/35 patients scoring at 8 or above on
the MMAS-8. This finding indicates that patients should be assessed for adherence regularly,
either by scale or by asking the patient and/or family members about medication regimens.
Reinforcement of education at follow-up appointments by discussing aspects of the patient’s
individualized treatment plan can assist in reminding patients about goals of treatment.
Knowledge empowers patients to participate in self-care activities, and with this
education about cholesterol, patients are empowered to monitor levels with the physician to
monitor improvement of the disease process. If diabetic patients track blood glucose levels and
pay attention to the glycosylated hemoglobin levels in the physician’s office, the LDL-C level
should be added to that list for the patient to track with the provider. They will remain informed
in this manner, and able to participate in the treatment plan, thus optimizing patient outcomes.
In order for this project to be sustained as a standard of care in the clinic, there must be a
method of supervision in place for implementation to continue. The Advanced Practice
Registered Nurse can offer supervision in this instance. Implementation and continuance of the
American College of Cardiology/American Heart Association guidelines in order to ensure
diabetic patients are placed either on moderate or high-intensity statin therapy and maintain
LDL-C levels of 70 mg/dl or less has the capacity to impact the diabetic patient population
significantly. The Advanced Practice Registered Nurse is able to screen patients for diabetes and
high cholesterol, educate about medication adherence and disease management, and give a
detailed explanation of any laboratory results analysis. As a provider, the APRN has the ability
to positively affect the diabetic population by making this group less susceptible to
cardiovascular disease through statin therapy adherence.
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Appendix B: SWOT Analysis from Family Practice Clinic
Strengths
§
§
§
§
§
§
§
§
§
§
§
§
§
§

Electronic Health Record foundation
Reputation for quality healthcare
Patient Portal present on website
Strong medical staff and strong
leadership
Problem-solving
Trust between staff members
Network partnerships (ex. WellMed)
High level of efficiency
Spanish language proficiency of
providers
Strong relationships with patients and
families
Interdisciplinary approach
Opportunities
Growing metropolitan community
Increasing aging and managed care
population
Expanding community health care
programs

Weaknesses
§
§
§
§
§
§
§

§
§
§
§

Lack of available written educational
resources
Difficulties in continuity of care
Lack of appropriate medication costs
Limited procedural/diagnostic
capabilities
Small clinic with some tight spaces
Slowed access to referring physician
documentation
Limited budget

Threats
Competition for specialty referring
physicians
Patient choice of primary care
provider
Lack of insurance related to high
unemployment rate
Reduction of government
reimbursement
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